Neos Therapeutics Inc (NASDAQ:NEOS): James E. Flynn’s Deerfield Management filed an amended 13D.
You can check out Deerfield Management’s latest holdings and filings here.
Please follow Deerfield Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Deerfield Management or update its stock holdings.
Follow James E. Flynn's Deerfield Management
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Deerfield Mgmt | 0 | 1,907,052 | 0 | 1,907,052 | 1,907,052 | 6.72% |
Deerfield Management Company | 0 | 2,633,845 | 0 | 2,633,845 | 2,633,845 | 9.08% |
Deerfield Mgmt III | 0 | 726,793 | 0 | 726,793 | 726,793 | 2.53% |
Deerfield Special Situations Fund | 0 | 1,691,146 | 0 | 1,691,146 | 1,691,146 | 5.96% |
Deerfield Partners | 0 | 127,384 | 0 | 127,384 | 127,384 | 0.45% |
Deerfield International Master Fund | 0 | 88,522 | 0 | 88,522 | 88,522 | 0.32% |
Deerfield Private Design Fund III | 0 | 726,793 | 0 | 726,793 | 726,793 | 2.53% |
James E. Flynn | 0 | 2,633,845 | 0 | 2,633,845 | 2,633,845 | 9.08% |
Page 1 of 18 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS
FILED PURSUANT
TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS
THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 1) *
Neos Therapeutics, Inc.
(Name of Issuer)
Common Stock
(Title of Class of Securities)
64052L106
(CUSIP Number)
August 21, 2017
(Date of Event Which Requires Filing of
this Statement)
Check the appropriate box to designate the
rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)
(Page 1 of 15 Pages)
———-
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder
of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 2 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 2 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 1,907,052 (1) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 1,907,052 (1) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,907,052 (1) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 6.72% | ||
12. | TYPE OF REPORTING PERSON* PN |
__________________
(1) Comprised of an aggregate of 1,593,411 shares of common stock and 313,641 shares of common stock
underlying convertible notes (based on the lowest conversion price of $7.00, subject to adjustment) held by Deerfield Special
Situations Fund, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P., of which Deerfield Mgmt, L.P. is
the general partner. The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion
of such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder
and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 9.985%
of the total number of shares of the Issuer then outstanding.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 3 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 3 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Management Company, | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 2,633,845 (2) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 2,633,845 (2) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,633,845 (2) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.08% | ||
12. | TYPE OF REPORTING PERSON* PN |
__________________
(2) Comprised of an aggregate of 1,692,921 shares of common
stock and 940,924 shares of common stock underlying convertible notes (based on the lowest conversion price of $7.00, subject
to adjustment) held by Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P.
and Deerfield International Master Fund, L.P., of which Deerfield Management Company, L.P. is the investment advisor. The provisions
of the convertible notes beneficially owned by the reporting person restrict the conversion of such securities to the extent that,
upon such exercise or conversion, the number of shares then beneficially owned by the holder and any other person or entities
with which such holder would constitute a Section 13(d) “group” would exceed 9.985% of the total number of shares
of the Issuer then outstanding.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 4 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 4 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Mgmt III, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 726,793 (3) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 726,793 (3) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 726,793 (3) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.53% | ||
12. | TYPE OF REPORTING PERSON* PN |
_________________
(3) Comprised of an aggregate of 99,501 shares of common stock
and 627,183 shares of common stock underlying convertible notes (based on the lowest conversion price of $7.00, subject to adjustment)
held by Deerfield Private Design Fund III, L.P., of which Deerfield Mgmt III, L.P. is the general partner. The provisions of the
convertible notes beneficially owned by the reporting person restrict the conversion of such securities to the extent that, upon
such exercise or conversion, the number of shares then beneficially owned by the holder and any other person or entities with
which such holder would constitute a Section 13(d) “group” would exceed 9.985% of the total number of shares of the
Issuer then outstanding.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 5 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 5 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Special | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 1,691,146 (4) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 1,691,146 (4) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,691,146 (4) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.96% | ||
12. | TYPE OF REPORTING PERSON* PN |
_________________
(4) Comprised of an aggregate of 1,377,505 shares of common
stock and 313,641 shares of common stock underlying convertible notes (based on the lowest conversion price of $7.00, subject
to adjustment). The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion of
such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder
and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 9.985%
of the total number of shares of the Issuer then outstanding.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 6 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 6 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Partners, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 127,384 | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 127,384 | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 127,384 | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.45% | ||
12. | TYPE OF REPORTING PERSON* PN |
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 7 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 7 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield International Master Fund, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION British Virgin Islands | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 88,522 | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 88,522 | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 88,522 | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.32% | ||
12. | TYPE OF REPORTING PERSON* PN |
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 8 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 8 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Deerfield Private Design Fund III, L.P. | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 726,793 (5) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 726,793 (5) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 726,793 (5) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 2.53% | ||
12. | TYPE OF REPORTING PERSON* PN |
_________________
(5) Comprised of an aggregate of 99,510 shares of common stock
and 627,283 shares of common stock underlying convertible notes (based on the lowest conversion price of $7.00, subject to adjustment).
The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion of such securities
to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder and any other
person or entities with which such holder would constitute a Section 13(d) “group” would exceed 9.985% of the total
number of shares of the Issuer then outstanding.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 9 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 9 of 15 |
1. | NAME OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) James E. Flynn | ||
2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* | (a) (b) ☒ | |
3. | SEC USE ONLY | ||
4. | CITIZENSHIP OR PLACE OF ORGANIZATION United States | ||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5. | SOLE VOTING POWER 0 | |
6. | SHARED VOTING POWER 2,633,845 (6) | ||
7. | SOLE DISPOSITIVE POWER 0 | ||
8. | SHARED DISPOSITIVE POWER 2,633,845 (6) | ||
9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,633,845 (6) | ||
10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN | ☐ | |
11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 9.08% | ||
12. | TYPE OF REPORTING PERSON* IN |
__________________
(6) Comprised of an aggregate of 1,692,921 common shares and
940,924 common shares underlying convertible notes (based on the lowest conversion price of $7.00, subject to adjustment) held
by Deerfield Private Design Fund III, L.P., Deerfield Special Situations Fund, L.P., Deerfield Partners, L.P. and Deerfield International
Master Fund, L.P. The provisions of the convertible notes beneficially owned by the reporting person restrict the conversion of
such securities to the extent that, upon such exercise or conversion, the number of shares then beneficially owned by the holder
and any other person or entities with which such holder would constitute a Section 13(d) “group” would exceed 9.985%
of the total number of shares of the Issuer then outstanding.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 10 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 10 of 15 |
Item 1(a). | Name of Issuer: | |
Neos Therapeutics, Inc. | ||
Item 1(b). | Address of Issuer’s Principal Executive Offices: | |
2940 Grand Prairie, TX 75050 | ||
Item 2(a). | Name of Person Filing: | |
James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P. and Deerfield Special Situations Fund, L.P. and Deerfield Private Design Fund III, L.P. | ||
Item 2(b). | Address of Principal Business Office, or if None, Residence: | |
James E. Flynn, Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Special Situations Fund, L.P., and Deerfield Private Design Fund III, L.P., 780 Third Avenue, 37th Floor, New York, NY 10017 | ||
Item 2(c). | Citizenship: | |
Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Deerfield International Master Fund, L.P. – James E. Flynn – United States citizen | ||
Item 2(d). | Title of Class of Securities: | |
Common Stock | ||
Item 2(e). | CUSIP Number: | |
64052L106 | ||
Item 3. | If This Statement is Filed Pursuant to | |
(a) | ☐ | Broker or dealer registered under Section 15 of the |
(b) | ☐ | Bank as defined in Section 3(a)(6) of the Exchange Act. |
(c) | ☐ | Insurance company as defined in Section 3(a)(19) of |
(d) | ☐ | Investment company registered under Section 8 of the |
(e) | ☐ | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
(f) | ☐ | An employee benefit plan or endowment fund in accordance |
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 11 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 11 of 15 |
(g) | ☐ | A parent holding company or control person in accordance |
(h) | ☐ | A savings association as defined in Section 3(b) of |
(i) | ☐ | A church plan that is excluded from the definition |
(j) | ☐ | A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); |
(k) | ☐ | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |
If filing as a non-U.S. institution in accordance
with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: _________________
Item 4. | Ownership. | ||
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. | |||
(a) | Amount beneficially owned**: | ||
Deerfield Mgmt, L.P. – 1,907,052 shares Deerfield Mgmt III, L.P. – 726,793 shares Deerfield Management Company, L.P. – 2,633,845 shares Deerfield Special Situations Fund, L.P. – 1,691,146 Deerfield Partners, L.P. – 127,384 shares Deerfield International Master Fund, L.P. – Deerfield Private Design Fund III, L.P. – 726,793 James E. Flynn – 2,633,845 shares | |||
(b) | Percent of class**: | ||
Deerfield Mgmt, L.P. – 6.72% Deerfield Mgmt III, L.P. – 2.53% Deerfield Management Company, L.P. – 9.08% Deerfield Special Situations Fund, L.P. – 5.96% Deerfield Partners, L.P. – 0.45% Deerfield International Master Fund, L.P. – Deerfield Private Design Fund III, L.P. – 2.53% James E. Flynn – 9.08% | |||
(c) | Number of shares as to which such person has**: | ||
(i) | Sole power to vote or to direct the vote: | All Reporting Persons 0 | |
(ii) | Shared power to vote or to direct the vote: | Deerfield Mgmt, L.P. – 1,907,052 Deerfield Mgmt III, L.P. – 726,793 Deerfield Management Company, L.P. – 2,633,845 Deerfield Special Situations Fund, L.P. – 1,691,146 Deerfield Partners, L.P. – 127,384 Deerfield International Master Fund, L.P. – 88,522 Deerfield Private Design Fund III, L.P. – 726,793 James E. Flynn – 2,633,845 | |
(iii) | Sole power to dispose or to direct the disposition of: | All Reporting Persons – 0 | |
(iv) | Shared power to dispose or to direct the disposition | Deerfield Mgmt, L.P. – 1,907,052 Deerfield Mgmt III, L.P. – 726,793 Deerfield Management Company, L.P. – 2,633,845 Deerfield Special Situations Fund, L.P. – 1,691,146 Deerfield Partners, L.P. – 127,384 Deerfield International Master Fund, L.P. – 88,522 Deerfield Private Design Fund III, L.P. – 726,793 James E. Flynn – 2,633,845 |
**See footnotes on cover pages which are incorporated by reference
herein.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 12 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 12 of 15 |
Item 5. | Ownership of Five Percent or Less of a Class. |
If this statement is being filed to report the fact that as | |
Item 6. | Ownership of More Than Five Percent on Behalf of Another Person. |
If any other person is known to have the right to receive or | |
N/A | |
Item 7. | Identification and Classification of the Subsidiary |
If a parent holding company or Control | |
N/A | |
Item 8. | Identification and Classification of Members of the Group. |
If a group has filed this schedule pursuant | |
See Exhibit B | |
Item 9. | Notice of Dissolution of Group. |
Notice of dissolution of a group may be furnished as an exhibit | |
N/A |
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 13 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 13 of 15 |
Item 10. | Certifications. |
“By signing below I certify that, to the best of my knowledge |
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 14 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 14 of 15 |
SIGNATURE
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 15 of 18 – SEC Filing
CUSIP No. | 64052L106 | 13G | Page 15 of 15 |
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Date: August 31, 2017
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 16 of 18 – SEC Filing
Exhibit List
Exhibit A. Joint Filing Agreement.
Exhibit B. Item 8 Statement.
Exhibit C. Power of Attorney (1).
(1) Power of Attorney previously filed as Exhibit 24 to a Form 3 with regard to Proteon Therapeutics,
Inc. filed with the Securities and Exchange Commission on August 4, 2017 by Deerfield Special Situations Fund, L.P., Deerfield
Partners, L.P., Deerfield International Master Fund, L.P., Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund
IV, L.P., Deerfield Mgmt, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P., and James
E. Flynn.
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 17 of 18 – SEC Filing
Exhibit A
Joint Filing Agreement
The undersigned agree that this
Schedule 13G, and all amendments thereto, relating to the Common Stock of Neos Therapeutics, Inc.
shall be filed on behalf of the undersigned.
DEERFIELD MGMT, L.P.
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MANAGEMENT COMPANY, L.P.
By: Flynn Management LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD MGMT III, L.P.
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD SPECIAL SITUATIONS FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PARTNERS, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD INTERNATIONAL MASTER FUND, L.P.
By: Deerfield Mgmt, L.P., General Partner
By: J.E. Flynn Capital, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
DEERFIELD PRIVATE DESIGN FUND III, L.P.
By: Deerfield Mgmt III, L.P., General Partner
By: J.E. Flynn Capital III, LLC, General Partner
By: /s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Follow Neos Therapeutics Inc. (NASDAQ:NEOS)
Page 18 of 18 – SEC Filing
JAMES E. FLYNN
/s/ Jonathan Isler
Jonathan Isler, Attorney-In-Fact